ArticleProstate cancer and prostatic diseases2018
Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram.
Article in Prostate cancer and prostatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessment of biochemical recurrence of prostate cancer (Review).International journal of oncology · 2019Pooled it
- Review
- Quantifying Suicide Risk in Prostate Cancer: A SEER-Based Predictive Model.Journal of epidemiology and global health · 2025Article
- Biochemical recurrence prediction after robot-assited radical prostatectomy (BCR-PRARP).Heliyon · 2025Article
- Article
- Establishment and Validation of a Novel Prediction Model for Early Natural Biochemical Recurrence After Radical Prostatectomy Based on Post-Operative PSA at Sixth Week.Cancer management and research · 2023Article
- Precision intervention for prostate cancer: Re-evaluating who is at risk.Cancer letters · 2022Review
- Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?Therapeutic advances in medical oncology · 2021Review
- PSA density of the lesion: a mathematical formula that uses clinical and pathological data to predict biochemical recurrence in prostate cancer patients.Revista do Colegio Brasileiro de Cirurgioes · 2021Article
- UICC and AJCC 8th edition tumor-nodes-metastasis (TNM) classifications for patients treated with radical prostatectomy: reliable but not infallible prognostic tools.Annals of translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly biochemical recurrence (eBCR) after radical prostatectomy (RP) heralds poor oncological outcomes and may be prevented with adjuvant radiation (aRT).
methodsWe developed a contemporary eBCR nomogram in 13 797 RP patients from Hamburg (2005-2016) and externally validated it in 5952 RP patients from Vienna. Receiver operating characteristics-derived area under the curve (AUC), Heagerty's C-index, and decision curve analysis (DCA) were used to quantify model accuracy and to compare the current tool with the Walz nomogram, the online Memorial Sloan Kettering Cancer Center (MSKCC) nomogram and the post-surgical Cancer of the Prostate Risk Assesment (CAPRA-S).
resultsThe eBCR nomogram relies on independent BCR predictors at 12 and 24 months after RP: preoperative PSA, pathological Gleason Score, tumor stage, lymph node, and surgical margin status. It achieved 81% accuracy at both time points in external validation. Additionally, the current nomogram yielded best calibration, optimal DCA results, and highest rates of avoided aRT in cutoff analyses, compared to the Walz nomogram, the MSKCC nomogram, and the CAPRA-S score.
conclusionsThe updated eBCR nomogram is easily applicable, highly accurate, and may allow avoiding immediate aRT in a large proportion of patients with few concomitant missed eBCR instances. It compares favorably to similar tools.
Indexed as
Identifiers
29487397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.